Neurology

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

Supported by Otsuka, new research calculated the value of daily hours spent on basic chores and complex tasks required to support a loved one with AD.

Your daily dose of the clinical news you may have missed.

Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.

Your daily dose of the clinical news you may have missed.

Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.

Your daily dose of the clinical news you may have missed.

Medicare’s restrictive coverage policies are denying patients with early Alzheimer's disease access to novel treatments. And private payers are following suit.

Help young patients with migraine (and their parents) get and stay prepared for the shift from home to college with this migraine survival kit checklist.

Your daily dose of the clinical news you may have missed.

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

Your daily dose of the clinical news you may have missed.

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.

Erenumab 140 mg safely and effectively induced remission in nonopioid MOH within 6 months in individuals for whom other preventive medications had failed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.

Based on its acceptance of the resubmission, FDA has assigned a PDUFA action goal date of January 31, 2025 for AXS-07.

Your daily dose of the clinical news you may have missed.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

ESC 2024: Cannabis, opioid, and MDMA use were most strongly tied to cardiovascular event risk, according to a new study.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Type 2 diabetes and prediabetes were associated with accelerated brain aging, particularly among men and persons with poor cardiometabolic health, according to new research.